Weight loss with GLP-1 receptor agonists is driven mainly by reduced energy intake. A recurring question in the literature — and among the people who follow it — is how much of the weight lost is fat and how much is lean tissue, principally skeletal muscle. This explainer sets out what the published body-composition data report, and where the evidence remains thin. It is research context, not guidance.
Why lean mass is measured at all
Body-composition substudies report fat mass, lean mass, visceral adipose tissue and liver fat separately rather than a single weight figure. The concern is that a meaningful share of total weight loss could be lean tissue, given that appetite suppression and reduced protein intake can accompany any large energy deficit. A 2026 review of GLP-1-derived therapies and sarcopenia argues for a specific focus on at-risk populations rather than one assumption for everyone [2].
The licensed GLP-1 and dual-incretin obesity trials each report their own body-composition figures, and the share of loss attributable to lean tissue varies with the agent, the dose and the imaging method used. What the class-level data do not yet provide is a single agreed figure.
The BELIEVE combination trial
The BELIEVE Phase 2 trial (Heymsfield et al., Nature Medicine 2026) randomised 507 adults with overweight or obesity across 26 sites. It combined semaglutide with bimagrumab, a monoclonal antibody that blocks the activin type II receptors and therefore the myostatin pathway — a mechanism unrelated to incretin signalling [1].
At week 72, the highest-dose combination (bimagrumab 30 mg/kg plus semaglutide 2.4 mg) produced a mean weight loss of 22.1%, against 15.7% with semaglutide alone and 10.8% with bimagrumab alone. Around 92% of the loss in the combination group was attributable to fat mass, and the reduction in lean mass was 2.9%, against 7.4% with semaglutide alone [1][3][4]. Bimagrumab is an antibody, not a peptide; it is included here because the trial defines the current evidence on how much lean mass a GLP-1 regimen can spare when a second mechanism is added.
The glucagon-agonist comparison
Survodutide, a dual glucagon/GLP-1 agonist, reported body-composition data from an MRI substudy of the Phase 3 SYNCHRONIZE-1 trial in 2026: liver fat fell by up to 63.1% and visceral fat by up to 34.0% at the 6.0 mg dose, with lean volume declining by 9.8% and the sponsor describing lean-mass change as no more than 11.3% of the change in total tissue mass [6]. The pattern in both datasets is the same — the class reduces fat disproportionately, but lean tissue is not untouched.
What the evidence does not show
The BELIEVE data are Phase 2, and bimagrumab is not licensed in the UK. The body-composition findings are trial endpoints, not functional outcomes such as strength, mobility or falls. The myostatin-pathway peptides sold as research compounds — follistatin, ACE-031 and the TB-500 misnomer — have no comparable human body-composition dataset; their human evidence is graded Anecdotal or Limited on this site. Nutrition, resistance training and protein intake are studied as modifiers of lean-mass change, but none substitutes for clinical care, and this site does not provide dosing or administration information. All compounds discussed here are research subjects; nothing in this piece is guidance for personal use.
UK status
Semaglutide and tirzepatide are licensed in the UK and available via private prescription and, within NICE-approved pathways, the NHS. Bimagrumab and survodutide are not licensed in the UK and are not available through any lawful UK supply route; under the Medicines Act 1968 and the Human Medicines Regulations 2012 they may not lawfully be supplied to patients here.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.